Studies of Bubolz et al. [3] and Haroche et al. [6-7] demonstrated some efficiency of the BRAF inhibitor vemurafenib in the treatment several patients with multisystemic and refractory ECD and LCH. This evidence concerns the gene BRAF and Langerhans cell histiocytosis.